Assessment of the economic evaluation of the contrast agent MultiHance
Abstract
Gadolinium based contrast agents are widely used in MRI in a diagnostic of variety of pathologies. The quality of contrast enhancement depends on the total dose (mM per kg body weight) and its relaxivity. Gadobenic acid (MultiHance® , Bracco Imaging S.p.A, Italy) has the highest relaxivity comparing to others gadolinium based contrast agents approved in Russia. The aim of the study is to conduct a health economic evaluation of gadobenic acid in contrast enhanced MRI. The cost effectiveness analysis, sensitivity analysis and budget impact analysis were used to modeling MRI of CNS, MR-angiography and MRI of the liver. In results, we can say that Multihance® is cost-effective comparing to gadopentetic acid, gadobutrol and gadodiamid in CNS MRI.
About the Authors
A. S. Kolbin
First Saint-Petersburg Pavlov State Medical University;
Saint-Petersburg State University
Russian Federation
Russian Federation
I. A. Vilum
First Pavlov State Medical University of St. Peterburg; National Medical and Surgical Center of the N.I. Pirogov
Russian Federation
Russian Federation
References
1. Основы лучевой диагностики и терапии: национальное руководство / гл. ред. тома акад. РАМН С.К. Терновой. — М.: ГЭОТАР-Медиа, 2012. — 992 с. (Серия «Национальные руководства по лучевой диагностике и терапии» / гл. ред.
2. Федеральная служба государственной статистики России. [Электронный ресурс]. URL: http://www.gks.ru/free_doc/new_site/population/demo/demo24. xls. Дата обращения 27.03.2014 г.
3. Thomsen H.S., Morcos S.K., Almén T., et al.Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines. EurRadiol. 2013;23(2):307-18.
4. Министерства Здравоохранения Российской Федерации. приказ №163 от 27.05.2011. Об утверждении отраслевого стандарта «клинико-экономиче-ские исследования. Общие положения».
5. Knopp M.V., Runge V.M., Essig M., et al. Primary and secondary brain tumors at MR imaging:bicentricintraindividual crossover comparison of gadobenatedimeglumine and gadopentetatedimeglumine. Radiology. 2004;230(1):55-64.
6. Rowley H.A., Scialfa G., Gao P.Y., et al. Contrast-enhanced MR imaging of brain lesions: a large-scale intraindividual crossover comparison of gadobenatedimeglumine versus gadodiamide. AJNR Am J Neuroradiol. 2008;29(9):1684-91.
7. Maravilla K.R., Maldjian J.A., Schmalfuss I.M., et al. Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents. Radiology. 2006;240(2):389-400.
8. Seidl Z., Vymazal J., Mechl M., et al. Does higher gadolinium concentration play a role in the morphologic assessment of brain tumors? Results of a multicenter intraindividual crossover comparison of gadobutrol versus gadobenatedimeglumine (the MERIT Study). AJNR Am J Neuroradiol. 2012;33(6):1050-8.
9. Colosimo C., Demaerel P., Tortori-Donati P., et al. Comparison of gadobenatedimeglumine (Gd-BOPTA) with gadopentetatedimeglumine (Gd-DTPA) for enhanced MR imaging of brain and spine tumours in children. PediatrRadiol. 2005;35(5):501-10.
10. Gerretsen S.C., le Maire T.F., Miller S., et al. Multicenter, double-blind, randomized, intraindividual crossover comparison of gadobenatedimeglumine and
11. gadopentetatedimeglumine for MR angiography of peripheral arteries. Radiology. 2010;255(3):988-1000.
12. Wang J., Yan F., Liu J., et al. Multicenter, intra-individual comparison of single dose gadobenatedimeglumine and double dose gadopentetatedimeglumine for MR angiography of the peripheral arteries (the Peripheral VALUE Study). J MagnReson Imaging. 2013;38(4):926-37.
13. Achenbach M., Figiel J.H., Burbelko M., et al. Prospective comparison of image quality and diagnostic accuracy of 0.5 molar gadobenatedimeglumine and 1.0 molar gadobutrol in contrast-enhanced run-off magnetic resonance angiography of the lower extremities. J MagnReson Imaging. 2010;32(5):1166-71.
14. Prokop M., Schneider G., Vanzulli A., et al. Contrast-enhanced MR Angiography of the renal arteries: blinded multicenter crossover comparison of gadobenatedimeglumine and gadopentetatedimeglumine. Radiology. 2005;234(2):399-408.
15. Brismar T.B., Dahlstrom N., Edsborg N., et al. Liver vessel enhancement by Gd-BOPTA and Gd-EOB-DTPA: a comparison in healthy volunteers. ActaRadiol. 2009;50(7):709-15.
16. Park Y., Kim S.H., Kim S.H., et al.Gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI versus gadobenatedimeglumine (Gd-BOPTA)-enhanced MRI for preoperatively detecting hepatocellular carcinoma: an initial experience. Korean J Radiol. 2010;11(4):433-40.
17. Клинико-экономический анализ (оценка, выбор медицинских технологий и управления качеством медицинской помощи). Под ред. Воробьева П.А. 2004, Ньюдиамед: М. 404 с.
18. Планирование и проведение клинических исследований лекарственных средств. Под ред. Белоусов Ю.Б. 2000, М.: Общество клинических исследователей. 579 с.
19. GoldM.R.Cost-eff ectivenessinHealthandMedicine. 1996, NewYork: OxfordUniversityPress. 425.
20. WalleyT., HaycoxА.,BolandA. Pharmacoeconomics. 2004: Elsevier Health Sciences. 216.
21. Оценка медицинских технологий, Рекомендации 2013 г. Под общей редакцией Белоусова Ю.Б. М.: Издательство ОКИ. — 2013.-40 с.
22. Ягудина Р.И., Куликов А.Ю., Нгуен Т. Определение «порога готовности платить» в России, в Европейских странах и в странах СНГ. Современная фармакоэкономика и фармакоэпидемиология. — 2011.- 4(1). — С. 7-13.
23. Brosa M.Principios, m?todos y aplicacionesdelan?lisis del impactopresupuestario en el sector sanitario. Pharmacoeconomics. Spanish Research Articles. 2005; 2 (2): 65-78.
24. Josephine A. Mauskopf et al. Principles of Good Practice for Budget Impact Analysis: Report of the ISPOR Task Force on Good Research Practices — Budget Impact Analysis. Value in Health. 2007; 10(5): 336-347.
25. Shellock F.G., Parker J.R., Pirovano G., et al. Safety characteristics of gadobenatedimeglumine: clinical experience from intra- and interindividual comparison studies with gadopentetatedimeglumine. J MagnReson Imaging. 2006;24(6):1378-85.
26. Schneider G., Sch?rholz H., Kirchin M.A., et al. Safety and adverse eff ects during 24 hours aſt er contrast-enhanced MRI with gadobenatedimeglumine (MultiHance) in children. PediatrRadiol. 2013;43(2):202-11.
27. Генеральное тарифное соглашение ОМС, г. Санкт-Петербург, [Электронный ресурс], URL: http://www.spboms.ru/kiop/main?page_id=338.
28. Цены на медицинские услуги СПБ ГУЗ «Городская покровская больница». 2014 г. [Электронный ресурс], URL: http://www.pokrov.spb.ru/stoimostq-uslug.html.
29. Прайс-лист производителя ЗАО «Имэкс».
30. Государственный реестр предельных отпускных цен. [Электронный ресурс], URL: http://www.grls.rosminzdrav.ru/pricelims.aspx.
31. Официальный сайт Российской Федерации в сети Интернет для размещения информации о размещении заказов на поставки товаров, выполнение работ, оказание услуг. Данные мониторинга открытых аукционов за 2013 г. [Электронный ресурс], URL: http://www.zakupki.gov.ru/epz/main/public/ home.html.
32. Тюрин И.Е. Лучевая диагностик в РФ — 2012 г. Материалы конференции «Радиология 2013».
Review
For citations:
Kolbin A.S., Vilum I.A. Assessment of the economic evaluation of the contrast agent MultiHance. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2014;(1):57-67. (In Russ.)
Views:
874
Email this article 